Alembic Pharmaceuticals Ltd has obtained final approval from the US FDA for its generic Bromfenac ophthalmic solution, used to treat postoperative inflammation and pain after cataract surgery. The approved product is equivalent to Prolensa Ophthalmic Solution, with an estimated market size of USD 168 million.
